IL-6 R alpha/CD126 hFc Chimera, Human

IL-6 R alpha/CD126 hFc Chimera, Human

Serum levels of interleukin-6 (IL-6) are increased in patients with type 2 diabetes (T2D). IL-6 exerts its pleiotropic effects via the IL-6 α-receptor (IL-6R), which exists in membrane-bound and soluble (sIL-6R) forms and activates cells via the β-receptor glycoprotein 130 (gp130).
Z05510
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
IL-6 R alpha/CD126 (Leu20-Pro365)
Accession # P08887-1		 hFc
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 65.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 85-110 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Background
Target Background Serum levels of interleukin-6 (IL-6) are increased in patients with type 2 diabetes (T2D). IL-6 exerts its pleiotropic effects via the IL-6 α-receptor (IL-6R), which exists in membrane-bound and soluble (sIL-6R) forms and activates cells via the β-receptor glycoprotein 130 (gp130).
Synonyms IL-6R subunit alpha; IL-6R-alpha; IL-6RA; IL-6R 1; IL6R; CD126; IL6RQ; gp80

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.